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Summary-Described are the synthesis and some aspects of the pharmacology of acetylseco 
hemicholinium-3 (acetylseco HC-3), the acetylated open ring analogue of hemicholinium-3 
(HC-3). The effects of both compounds were determined in uiuo on rat brain acetylcholine 
(ACh), ‘Y-choline (14C-Ch) incorporation into 14C-acetylcholine (14C-ACh) and on one way 
jump box avoidance and escape behavior in naive and trained rats. In addition, the in vitro 
effects of both drugs were determined on choline acetyltransferase activity (ChAc) in rat brain. 
When given intraventricularly in doses of l-20 pg both compounds reduced total ACh 
content in the brain to a maximum of 5’0% of normal in 30-60 min. In doses of 20 pg intra- 
ventricularly, both drugs also reduced 14C-Ch incorporation into Y-ACh by 845% for 
acetylseco HC-3 and by 52% for HC-3. 
The in viva changes of ACh in the brain were correlated with the behavioral deficits induced 
in one way shuttle box acquisition and retention. In doses of 20 pg total intraventri~ularly, 
both compounds produced behavioral deficits which were greater in naive than in trained 
animals. Zn vitro, acetylseco HC-3 inhibited ChAc activity with an 150 of 1 x 10e5 M with 
Ch IO-* M and acetyl CoA 6.4 x 10m4 M, while HC-3 had no inhibitory effects. Using rat 
brain homogenate as the enzyme source and commercial acetyl CoA for kinetic studies, acetyl- 
seco HC-3 was shown to be a mixed inhibitor of acetyl CoA and a competitive inhibitor of Ch. 
The in uiuo actions of acetyiseco HC-3 are consistent with those of a ChAc inhibitor. However, 
it is necessary to rule out the possibility that the drug may also compete with Ch for its transport 
across biological membranes like its deacetylated derivative HC-3. 
The hemicholiniums have been widely investigated since they were first synthesized in 1954 
by LONG and SCHUELER. Hemicholinium-3 (HC-3) is the prototype compound of this 
series. This agent reduces tissue acetyfcholine (ACh), possibly by reducing the active 
transport of choline (Ch) as shown by MACINTOSH (1963) and HODGKIN and MARTIN (1965). 
However, other mechanisms such as a shift in Ch metabolism toward phospholipid forma- 
tion (G~MEz, DOMINO and SELLINGER, 1970a,b; GOMEZ, SELLINGER, SANTIAGO and 
DOMINO, 1971) and production of a false neurotransmitter through acetyhttion (RODRIGUEZ 
DE LORES ARNAIZ, LIEBER and DE ROBERTIS, 1970) have been proposed. SCHUELER (1955) 
found that WC-3 was the most toxic of some 20 bis-quaternary derivatives studied. HC-10 
or acetylseco hemicholinium-3 (acetylseco HC-3) produced a toxicological picture similar 
to HC-3. SCHUELER assumed that acetylseco HC-3 was hydrolyzed in viuo to HC-3. There 
was little evidence then that acetylseco HC-3 was pharmacologically different from HC-3. 
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The chemical structures of these two compounds are given in Figure 1. Note that HC-3 
exists in the hemiacetal form. The fact that “ hemiacetal ” formation in the ring of HC-3 
is not essential for neuromuscular blocking effects (GESLER, LASHER, HOPPE and STECK, 
Hemicholinium -3 
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Fig. 1. Comparison of structures of acetyiseco HC-3 and HC!-3. 
Note that both compounds are bisquaternary nitrogen derivatives. HC-3 exists as the hemiacetyl 
ring structure. 
1959) and that acetylseco l-K-3, the acetate derivative of the opened ring form of He-3 
cannot exist in the hem&eta1 form suggests that acetylseco HC-3 might possess different 
pharmacological actions. 
MAGGIO and HAARSTAD (unpublished observations) have reported critical pharmacological 
differences between HC-3 and acetylseco HC-3 in which inhibition ofcholine acetyltransferase 
(a&y1 CoA-choline 0-acetyltransferase EC2.3.1 Xi, ChAc) by the latter is especially prom- 
inent (DE B&BIAN VERSIXR, HAARSTAD and WHITE, 1968, 1969). The present manuscript 
describes further some of the pharmacological properties of acetylseco HG3 which indicate 
it to be an important new tool to inhibit ACh synthesis in the brain when the drug is given 
intraventricularly. 
METHODS 
The compound, u,cw-dibromo-4,4’-biacetophenone, which is a precursor for acetylseco 
HC-3, was prepared according to the method of HAARSTAI) and SCHUE~ER (unpublished 
observations) which is a modification of the method of LONG and SCHUELER (1954). Acetyl- 
seco HC-3 dibromide, [4,4’-diphenylylenebis (2-oxoethylene)] bis [(Zacetoxyethyl) dimethyl- 
ammonium bromide], was prepared as follows: 0.5 g of ff,u-dibrom~,~-bia~tophenone 
was dissolved in SO ml of boiling tetrahydrofuran. The solution was allowed to cool to about 
50°C. Two ml of freshly distilled 2-dimethylaminoethyl acetate was added all at once while 
the solution was being swirled. A white precipitate began to form almost immediately. The 
mixture was allowed to stand at room temperature for 7 hr. The mixture was filtered through 
a sintered glass funnel. The precipitate was washed well with tetrahydrofuran, then diethyl 
ether and dried in a vacuum desiccator over anhydrous calcium chloride. Yield O-7 g (85%) 
(m.p., becomes an amber glass at 195”, begins to blacken at 205°C. (uncorr.); ImaX 305 nm, 
log Qn, 4.52; acetate carbonyl, 5.73 pm (s) ketone carbonyl, 5.91 ,um (s). Anal. Calcd for 
CzsH,,BrzNz02: C, 51.08% ; H, 5.82% ; N, 4.25%. Found C, 50.91% ; H, 5.60; N, 3.99%. 
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It should be noted that acetylseco HC-3 is prepared analytically pure without the use of a 
recrystallization step. This has been demonstrated by analyses of several separate prepara- 
tions. This is to obviate the possibility of transesterification which would lead to the forma- 
tion of HC-3 itself. 
Animal preparations 
Male Holtzman rats in groups of 6-12 were used throughout. Both young rats (20-30 days 
old) as well as adults (90 days and older) were used with intraventricular injection of HC-3 
and acetylseco HC-3 in various experiments involving steady state, ACh depletion and 
14C-choline (14C-Ch) incorporation into “C-acetylcholine (14C-ACh). All drug doses were 
calculated as base. Control solutions of equimolar amounts of NaBr were also used. The 
young rats were anaesthetized with diethyl ether-air and the bregma exposed to use as a 
reference point. A puncture point was made on one side approximately 13 mm posterior 
and 13 mm lateral from the bregma to inject either HC-3 or acetylseco HC-3 in the area 
of the lateral ventricle. A microliter syringe and a needle with a stop were used to inject 
to a depth of 4-4.5 mm. Rats usually recovered 3-4 min later from anaesthesia and were 
killed 3 hr later by guillotine. Brains were removed within 45 set for various assays. Male 
Holtzman rats 90 days and older were implanted with polyethylene cannulae as described 
by ROBINSON, HENGEVELD and DE BALBIAN VERSTER (1969) and ALTAFFER, DE BALBION 
VERSTER, HALL, LONG and D’ENCARNACAO (1970) under pentobarbital anaesthesia. Animals 
were used 7-14 days after cannulation similar to the young rats except that no anaesthetic 
was involved on the day of the experiment. Sacrifice occurred 10 min after intraventricular 
injection of 14C-Ch. 
Acetylcholine assay 
After sacrifice by decapitation brains were removed, homogenized and ACh extracted 
by the acidic alcohol method described by STONE (1955) and CROSSLAND (1961). Extracts 
were bioassayed on the frog rectus abdominus muscle as per DREN and DOMINO (1968). As 
suggested by FELDBERG (1945), ACh standards were prepared in alkali-inactivated extracts 
to control for the presence of sensitizing factors in the brain tissue. Although acetone 
(85x)-1N formic acid (15%) has been reported to be a superior extraction procedure 
(TORU and APRISON, 1966), it was not used in the bioassay experiments reported because 
in our hands the frog rectus muscle responded less reproducibly. This extraction procedure 
was used, however, for the radiochemical studies described below. 
Choline acetyltransferase assay 
Adult rat brains were used as a source of choline acetyltransferase (ChAc). On the day 
of the experiment, a rat was decapitated, the brain quickly removed, weighed, and a 10% 
homogenate prepared with distilled water. The ChAc assay procedure was a modification 
by DE BALBIAN VERSTER of the method of SCHRIER and SCHUSTER (1967) and MCCAMAN 
and HUNT (1965). The final concentration of the buffer substrate was: O-3 M sodium chloride, 
0.01 M choline chloride, 2 x lo- 4~ physostigmine, 0.02 M magnesium sulphate, 0.05% bovine 
plasma albumin, 0.08~ potassium phosphate (pH 7.4) and 6.2 x 10m4~ acetyl CoA. 
1 4C-Acetyl CoA was mixed with cold acetyl CoA to yield approximately 20,000 dis/min per 
incubation tube. Ten ~1 of the 10% homogenate (1 mg tissue equivalent) were pipetted into 
each incubation tube. One hundred ,~l of the substrate were then added with an automatic 
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pipetter. The tubes were incubated for 30 min at 37°C after which the reactions were termi- 
nated by placing the tubes in a boiling water bath for about 5 min. The reaction mixture 
was then placed onto 0.5 x 80 cm columns (diSPo pipets) prepared from prewashed Dowex 
1 x 8 .chloride. The incubation tubes were then washed with 3 consecutive 0.5 ml water 
washes, each wash being applied to the Dowex column. The effluent was collected directly 
into scintillation vials, 15 ml of dioxane scintillation fluid (8.0 g PPO, 0.1 g POPOP, 110 g 
naphthalene, 1 1 dioxane) was added to each vial and the samples counted in a Beckman 
ambient temperature scintillation counter. 
Incorporation of “C-choline into “C-acetylcholine 
Unanaesthetized adult male Holtzman rats cannulated at least one week previously were 
used. Drug and control rats were always done together. Ten min after injection of 20 1.11 
1 4C-Ch (1 $i ; 61 mCi/mm) alone or simultaneously with acetylseco HC-3 (20 pg base), 
the rat was decapitated, the brain quickly removed, weighed, and homogenized in acetone: 
IN formic acid (85 : 15). The extraction method of TORU and APRISON (1965) as adapted 
by SAELENS, ALLEN and SIMKE (1970) was used. After the separation of the organic and 
HZ0 extracts, paper electrophoresis as described by POTTER and MURPHY (1967) and 
SAELENS et al. (1970) was used to separate Ch and ACh in the H,O extract. The areas were 
visualized in iodine vapor and the appropriate sections placed into scintillation vials. One ml 
H,O and 10 ml of the above described dioxane solution were added to each vial. Counting 
was done in an ambient temperature Beckman scintillation counter. 
One way avoidance behavior 
The effects of intraventricular acetylseco HC-3, HC-3, and different equimolar amounts 
of NaBr for the two compounds were studied on acquisition and retention of rat one way 
avoidance behavior. The apparatus used was an adaptation of that used by CALDWELL, 
OBERLEAS, CLANCY and PRAASAD (1970) as described by TENEN (1966). The behavioral 
parameters were as follows: The conditioned stimulus (CS) was a 5 set presentation of four 
7.5 W red lights with the simultaneous presentation of an escape ledge. At the end of 5 set, 
the CS overlapped with a 5 set unconditioned stimulus (US) that consisted of 1 mA 60 Hz 
electric shock delivered to the grid floor. When the rat jumped on the ledge, the sequence 
was terminated. A 30 set ledge rest period then ensued. If at the end of this time the animal 
still persisted in sitting on the ledge, it was automatically pushed off by an electromechanical 
moving wall. Random intertrial intervals were maintained with a mean of 30 set and a range 
of 15-60 sec. After intraventricular injection, a 10 min period was allowed before animals 
were given 50 trials. The entire session lasted about 1 hr. Naive animals were given a total 
of 50 acquisition trials under the drug and discarded. Trained animals were given 50 trials 
per day for 5 consecutive days to achieve a 90% avoidance criterion and then used for the 
drug studies. 
RESULTS 
Comparative effects of acetylseco HC-3 and HC-3 on brain acetylcholine 
In view of the fact that quaternary nitrogen derivatives do not readily penetrate the blood- 
brain barrier, both HC-3 and acetylseco HC-3 were given intraventricularly to young rats 
+ hr prior to sacrifice. In Figure 2 the dose-effect relationships and per cent mortality are 
shown for groups of 6-10 rats per dose. Acetylseco HC-3 had a wider separation between 
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Fig. 2. Dose-effect relations of intraventricular acetylseco HC-3 and HC-3 on 
acetylcholine. 
rat brain 
On the x axis is plotted the dose as base of the compound listed given intraventricularly. 
At 0 dose an equimolar amount of sodium bromide to 20 pg hemicholinium bromide was given. 
The mean f SE. for 6-12 rats is shown. Increasing doses of intraventricular acetylseco HC-3 
(A-SECO) and HC-3 reduce total brain ACh and increase mortality. Note that acetylseco 
HC-3 is more potent in reducing brain ACh and is less toxic. All animals were killed & hr after 
drug administration. 
the dose that lowers ACh in brain and lethality than HC-3. Furthermore, it was much more 
effective in reducing ACh at lower doses than HC-3. HC-3 appeared to be a more toxic 
compound than acetylseco HC-3. With either compound in doses of 50 pg intraventricularly 
there was a 50% mortality. Animals that received HC-3 exhibited shaking, twitching, rigid 
posture, sometimes convulsions and respiratory arrest. These effects were especially obvious 
with larger doses. After acetylseco HC-3 rats did not exhibit any of the characteristic 
behavior induced by HC-3. In general, they were not very responsive to handling. Both 
drugs caused over a 50% loss of ACh with larger doses. After about 1 pg of acetylseco HC-3 
and 20 pg HC-3, no further drop in ACh was produced in rats that survived up to 3 hr after 
injection. 
Time course of brain acetylcholine depletion following acetylseco HC-3 and He-3 
In young rats intraventricular acetylseco HC-3 and HC-3 in doses of 20 pg total produced 
similar rates of brain ACh depletion which was maximal 30-60 min after injection. Groups 
of 8-10 rats were injected and sacrificed at 5, 15, 30 and 60 min later. The effects of acetyl- 
seco HC-3 appeared to be somewhat more rapid in onset in lower doses intraventricularly 
but both drugs showed similar levels of depletion of brain ACh at 60 min. 
Acetylseco HC-3 inhibition of choline acetyltransferase activity in vitro 
Rat brain ChAc activity was determined in oitro at different concentrations of acetylseco 
HC-3 and HC-3 varying from lo- 7 to IO-’ M. Choline was present at lo- ’ M and acetyl 
CoA at 6.4 x 10m4 M. The results of one experiment are shown in Figure 3, plotted as 
percent of control ChAc activity. HC-3 had no effect on ChAc activity. In contrast, acetyl- 
seco HC-3 was an inhibitor with an ISo of 1 x lo- 5 M under these substrate concentrations. 
When this experiment was repeated with different batches of acetylseco HC-3 and acetyl 
CoA, the I,, values varied from 5 x 10 -6 M to 1 x lo- ’ M. The fact that several batches of 
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Fig. 3. Comparative effects of acetylseco HC-3 and HC-3 on choline acetyltransferase. activity 
of rat brain homogenate. 
On the x axis is given the molar concentration of the 2 compounds and on they axis the per cent 
of control ChAc activity. The mean *LE. of 4 separate determinations at each point is given. 
The substrate concentration for choline was 1 x 10m2 M and for acetyl CoA 6.4 x 10e4 M. Note 
that acetylseco HC-3 is an effective ChAc inhibitor with an I 5o of 5 x 10e6 M at these substrate 
concentrations. 
acetylseco HC-3 showed similar chemical analyses and caused similar in u&o decreases in 
brain ACh when given intraventricularly suggests that the change in I,, values is due to 
different batches of commercial acetyl CoA. This problem has been observed by others 
using commercial acetyl CoA preparations containing impurities (FONNUM, 1969; 
SCHUBERTH, 1971). Nevertheless, the results of the present experiments are clear in that 
acetylseco HC-3 is an inhibitor of ChAc activity but HC-3 is not. 
The mode of inhibition of ChAc by acetylseco HC-3 seems complex. DEBALBIAN VERSTER 
et al. (1968) found that it was competitive with acetyl CoA and non-competitive with 
choline. Our own data with crude brain enzyme preparations and unpurified commercial 
acetyl CoA suggests it is mixed. In Figures 4 and 5 are the summarized data of individual 
experiments in which the reciprocal of varying concentrations of acetyl CoA and Ch are 
plotted against the reciprocal of enzyme activity. These particular Lineweaver-Burk plots 
were determined using 1 x lo- 5 M acetylseco HC-3. Statistical estimates of the K, and 
I&, were obtained using the computer analysis of WILKINSON (1961). In Figure 4 acetyl 
CoA concentrations varied from 3-1 x lo- ’ M to 3.1 x lo- 5 M. Choline concentration was 
lo-’ M. All other substrates in the incubation mixture were as described in the Methods. A 
V,,, for acetyl CoA of 0.28 &- 0.01 pmol/g per min was obtained without acetylseco HC-3 
and 0.19 + 0.02 ,umol/g per min after the inhibitor. The K, without acetylseco WC-3 was 
5.1 + 0.65 x 10V4 M and 1.4 f 0.34 x lo- 3 M with 1 x lo- 5 M acetylseco HC-3. These 
values depict a change caused by the presence of acetylseco HC-3 for both the V,,, and the 
K,,, of acetyl CoA. The results of an earlier experiment using different batches of drug and 
substrates also showed changes from normal in both V,,, and K,,, (see Table 1). The inhibi- 
tion suggested by the use of a crude enzyme preparation and unpurified commercial acetyl 
CoA in the presence of acetylseco HC-3 is neither clearly competitive nor non-com~titive 
but might be classified as mixed (WEBB, 1963). 
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Fig. 4. Lineweaver-Burk plot of the inhibitory effects of acetylseco HC3 on choline acetyl- 
transferase activity of rat brain homogenate with varying acetyl CoA concentrations and 
constant choline. 
Note that a mixed inhibition is observed. The K,,, and V max are given using the statistical 
estimate technique of WILKINSON (1961) for a range of 7.5 x 1O-3-4.5 x 10e6 M. A smaller 
range is shown for the individual experiment whose data are plotted on this graph. 
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Fig. 5. Lineweaver-Burk plot of the inhibitory effect of acetylseco He-3 on choline acetyi- 
transferase activity of rat brain homogenate with varying concentrations of choline and constant 
acetyl CoA. 
Note that a competitive inhibition is observed. The K,,, and V,,,.. are given using the statistical 
estimate techniques of WILKINSDN (1961) for a range of 1 x 10V5 M. A smaller range is shown 
for the individual experiment whose data is plotted in this graph. 
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Table 1. Kinetic values for mean choline acetyltransferase activity f S.E. of rat brain homogenate before 
and after acetylseco HC-3 
Molar range 
lM-IO-’ M 
IO-” M-1O-5 M 
lo-’ M-5 X lo--’ M 
IO-’ M-1o-5 M 
Choline control Acetylseco HC-3 (5 x 1O-6 M) 
V tnax V max 
Km (M) (pmol/g per min) K, (M) (pmol/g per min) 
f S.E. f S.E. f SE. rt: S.E. 
4.02 x 1O-4 f 1.12 0.238 + 0.009 1.04 x 10-d f 0.31 0.236 zt 0.014 
5.4 x lo-4f0.74 0.222 * ONI8 6.0 x lo-“* 1.15 0.182 f 0.012 
1.1 x 10-3 f 0.19 0.162 * O+IO9 1.4 x lo-3*0.35 0.119 + 0.011 
1.3 x 10-3+0~11 0.225 f 0.006 6.9 x 1O-J& 1.85 0.206 & 0.020 
Acetyl CoA control Acetylseco HC-3 (5 x 10m6 M) 
7.5 x10-3M+5 x10-6hl 3.4 x lo-4*0.41 0.388 f 0.014 4.3 x10-3 * 0.5 0.230 f 0.008 
3.1 X10-3hi-3.1 X 1@-5M 5.1 x 1O-4 kO.65 0.284 f 0.014 1.43 x 10-Z f 0.34 0.192 + 0.017 
Lineweaver-Burk analysis of data obtained by varying Ch from lo- ’ to lo- 5 M is shown 
in Figure 5. Acetyl CoA was held constant at 6.4 x 10m4 M. A Vm,, for Ch of 0.23 + 0.01 
pmol/g per min without acetylseco HC-3 and 0.21 + 0.02 pmol/g per min with acetylseco 
HC-3 was obtained. The K,,, without acetylseco HC-3 was 1.3 + 0.11 x IO- 3 M and 
6.9 f 1.9 x 10e3 M with this inhibitor. It would appear that in this particular experiment, 
and at the molar ranges depicted, competitive inhibition is involved. Several other experi- 
ments performed over a period of one year with different batches of acetyl CoA and acetyl- 
seco HC-3 produced similar results, as shown in Table 1. 
Effect of intraventricular acetylseco HC-3 and HC-3 on “C-choline incorporation into 
“C-acetylcholine in vivo 
As described in the Methods, 14C-Ch in a dose of 160 nmol and 1 &i was given intra- 
ventricularly to unanaesthetized adult rats with indwelling polyethylene brain cannulae. A 
time interval of 10 min between injection and decapitation was chosen to minimize the effects 
of counting recycled r4C-Ch and because our previous experiments indicated incorporation 
of at least 5% i4C-Ch into 14C-ACh at this time. The effects of acetylseco HC-3 and HC-3 
on in vivo incorporation of 14C-Ch into i4C-ACh are shown in Figure 6. The values of at 
least 6 animals per drug are normalized as per cent change from control. Acetylseco HC-3 
drastically reduced i4C-Ch incorporation into r4C-ACh to 15.5 + 1.1% of control. HC-3 
in equal amounts (20 p(g) reduced 14C-Ch incorporation to 48.0 f9.6%. The mean f S.E. 
extractable free pool of r4C-Ch was 157.5 + 15.5% after acetylseco HC-3 and only 
118.4 + 5.7% after HC-3. These differences areboth statistically significant (P < 0.001 for 
acetylseco HC-3 and P < 0.05 for HC-3). 
Comparative effects of acetylseco He-3 and He-3 on rat one way jump box avoidance and 
escape behavior 
Groups of 8-l 2 rats were studied on acquisition and performance in a jump box following 
intraventricular equimolar NaBr and 20 pg intraventricular acetylseco HC-3 and HC-3. 
Both of these compounds reduced brain ACh to about 50% of control within 3 hr. Ten 
minutes after intraventricular injection rats were given 50 trials which lasted about 1 hr. 
Both naive and trained (90% avoidance criterion) animals were run. The data obtained are 
given in a bar graph format as mean per cent of total response + S.E. for each series in 
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Fig, 6. Effects of acetylseco HC-3 and He-3 on ‘%choline inco~orat~on into ~~~-a~tyl~holine 
in rat brain. 
Both drugs (20 pg total) as well as W-Ch (I &i total, Specific Radioactivity 61 mCi/mm) 
were given intraventricularly to groups of 6 adult rats with indwelling polyethylene cannulae. 
The drug and L4C-Ch were given simultaneously and the animals sacrificed IO min later. Control 
animals received 20 ~1 intraventricularly of 0.9 % NaCl. The data are normalized so that control 
levels of ‘Y-Ch incorporation in ACh represent 100%. 
Figure 7. Both acetylseco HC-3 (P < O-01) and HC-3 (P < 0.001) significantly reduced 
acquisition and increased escape responding of naive as well as trained animals. Naive 
animals were more affected than trained animals. HC-3 produced more behavioral toxicity 
than acetylseco HC-3 even though both drugs reduced total brain ACh to similar levels. 
Gross behavioral alterations such as tremors were also more obvious following HC-3, 
DISCUSSION 
Several classes of ChAc inhibitors are now known. All have some disadvantages as 
neuropharmacological tools. Sulphhydryl inhibitors such as iodoacetate and p-chloro- 
mercurib-enzoate are relatively nonspecific (RELSBERG, 1957; MANNERVIK and SORBO, 1970). 
Cysteine is also a ChAc inhibitor but in excessive concentrations (MORRIS, HEBB and BULL, 
1966). Several halogen derivatives of ACh are known to be uncompetitive inhibitors of 
ChAc in concentrations of 6 x IO-’ M (PERSSON, LAIRSON, SCHUBERTH and Sonno, 1967; 
MORRIS and GREWAAL, 1969; HENDERSON and RAMA SASTRY, 1972). Perhaps the best known 
inhibitors of this enzyme are the styryIpyridine analogues (ALLEN, CARLSON and CAVALLITO, 
1970; CAVALLITO et at., 1969, 1970a,b; SMITH, CAVALLIT~ and FOLDES, 1967; WHITE and 
CAVALLITO, 1970). To this Iist of ChAc inhibitors one can add acetylseco HC-3. The com- 
pound is clearly different from HC-3, although it does share other pharmacolo~~l actions 
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Fig. 7. Comparative effects of acetylseco HC-3 on rat one way avoidance and escape behavior. 
Both drugs were given intraventricularly in a total dose of 10 pg to adult rats with indwelling 
cannulae. Equimolar amounts of sodium bromide were given for acetylseco HC-3 and HC-3. 
The hatched bars represent avoidance, the open bars escape, and the solid black bars no 
response. After each treatment these add to 100’~ total responses. The height of each bar 
represents the mean and the small vertical lines f S.E. for avoidance and escape data only. 
The data from naive animals is to the left and trained animals to the right. Note that both 
agents depressed acquisition of avoidance more than escape behavior in both naive and well 
trained animals but that HC-3 is more potent. All the animals were run 10 min after intra- 
ventricular injection for a total of 50 trials which lasted approximately 1 hr. Note that both 
drugs affected naive more than trained animals. Each bar graph represents the mean f SE. of 
8-12 animals. A group comparison f-test of control and drug treated groups was done. 
Significant differences of P for avoidance behavior are shown as ** < 0.01 and *** < 0401. 
of HC-3, including reduced toxicity after Ch (MAGGIO, 1968; MAGGIO and HAARSTAD, 
unpublished observations). The fact that acetylseco HC-3 is a bischoline ester makes it 
susceptible to hydrolysis, although strangely it has not been reported to be a substrate for 
cholinesterase in vitro. 
Studies of the action of intraventricular HC-3 and acetylseco HC-3 on total rat brain 
ACh indicate that both reduce ACh, although with different doses, times and lethality. 
Because of these differences, a study of the in vitro effects of these compounds on rat brain 
ChAc was deemed important. HC-3 was shown to have no effect while acetylseco HC-3 
was found to be a potent inhibitor (Fig. 3), an indication that the two compounds were 
both reducing brain ACh through different mechanisms. This does not rule out, however, 
the possibility that acetylseco HC-3 also affects the transport of Ch in a manner similar to 
HC-3. Like HC-3, acetylseco HC-3 is found to markedly alter normal liver metabolism 
producing fatty liver (MAGGIO and HAARSTAD, unpublished observations). The fact that 
Ch reverses many of the pharmacological actions of acetylseco HC-3 is further suggestion 
of an action on Ch transport. 
Kinetic studies using Lineweaver-Burk analysis do indicate that acetylseco HC-3 is a 
competitive inhibitor of Ch. Acetylseco HC-3 also has many similarities with ACh. MAGGIO 
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and HAARSTAD (unpublished ob~rvations) found acetylseco HC-3 to be a potent para- 
sympathom~etic additive with ACh. HC-3 did not exhibit these properties. Ileum con- 
tractions elicited by acetylseco HC-3 were blocked by atropine but not hexamethonium. 
Studies of base-catalyzed hydrolysis indicate that the ACh moiety of acetylseco HC-3 is 
similar in chemical reactivity to ACh. If acetylseco HC-3 has similarities to ACh, it could be 
acting like ACh through substrate inhibition of ChAc. KAITA and GOLDBERG (1969) have 
shown that increasing amounts of ACh produce competitive inhibition with Ch. If acetylseco 
HC-3 is occupying the choline site on the enzyme (as ACh would), there would be no acetyl- 
ation of Ch. There would be no competition for the enzyme site normally occupied by acetyl 
CoA. Our enzyme kinetics, however, indicate a mixed type of interaction with acetyl CoA. 
It might be that the greater size of the acetylseco IX-3 molecule is creating a physical 
hindrance to the attachment of acetyl CoA to the enzyme site. 
Of special importance are further studies using purified ChAc to better define the kinetics 
of inhibition by acetylseco HC-3. The studies reported in this paper should be regarded as 
preliminary in view of the use of commercially available 14C-acetyl CoA and rat brain 
homogenate as the enzyme source. In spite of these shortcomings, the data indicate that 
acetylseco HC-3 may become an important neuropharmacological tool. Results of intra- 
ventricular injections of acetylseco HC-3 or HC-3 simultaneously with pulse doses of 
14C-Ch further indicate that acetylseco HC-3 has a more potent effect than HC-3 on incor- 
poration of Ch into ACh. Again, this does not eliminate the possibility that acetylseco 
HC-3 affects Ch transport as well as inhibition of ChAc. Its greater potency than HC-3 
for reduction of ACh could be due to the combined effects of the two actions. DIAMOND and 
KENNEDY (1969) have shown that HC-3 inhibits incorporation of choline into phosphoryl- 
choline. The possibility that acetylseco HC-3 may also do the same must also be studied. 
The behavioral effects of intraventricular acetylseco HC-3 as well as HC-3 indicate that 
these agents are useful in altering brain function in animals. Unexpectedly HC-3 produced 
greater behavioral toxicity than acetylseco HC-3. Furthermore, tremors were also more 
obvious after WC-3, suggesting it has further differences in action from acetylseco HC-3. 
Of special interest is the fact that 4-( I-naphthylvinyl) pyridine hydrochloride (NVP), one 
of the potent styrylpyridine derivatives of CAVALLITO et al. (1969, 1970a, b), had negligible 
behavioral effects in rats unless massive doses were given i.p. (GOLDBERG, SLEDGE, ROBI- 
CHAND and DUBINSKY, 1972). Of course, this may have been because NVP does not readily 
penetrate the blood-brain barrier. In the present study acetylseco HC-3 was given intra- 
ventricularly to avoid its obvious peripheral effects when given parenterally. Further studies 
comparing intraventricular NVP and acetylseco HC-3 on various animal behaviors and 
possible antagonism by Ch would be of considerable interest. 
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